newsfilter
← Latest News
GlobeNewswire·

Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to include overall survival benefit versus standard of care Over 9,000